Novartis reports positive interim Phase III data for Zolgensma gene therapy candidate in SMA type 1 httpsfirstwordpharma.comnode1635611tsid28®ionid6Â
Novartis reports positive interim Phase III data for Zolgensma gene therapy candidate in SMA type 1 https://firstwordpharma.com/node/1635611?tsid=28®ion_id=6 …
More From BioPortfolio on "Novartis reports positive interim Phase III data for Zolgensma gene therapy candidate in SMA type 1 https://firstwordpharma.com/node/1635611?tsid=28®ion_id=6 …"